Latest

The company hopes the rebranding effort will better align with its work in cell culture media manufacturing.

The company’s Phase III setrusumab trials in osteogenesis imperfecta missed fracture endpoints but showed strong bone density gains.

In the final part of an interview with Petra Dieterich and Jeffrey Mocny of Abzena, the current tariff situation in the United States and beyond is considered.

Biomanufacturing is shifting toward more resilient and digitized networks for enhanced supply security amid global and supply-chain volatility.

In the biopharma industry during 2025, quality, tariffs, MFN pricing, and strategic outsourcing deals drove innovation and investment.

Key 2025 FDA draft and final guidances emphasize the modernization of biotech regulations, acceleration of rare-disease therapies, and streamlining of biosimilar pathways.

The complications of conjugate molecules, such as oligonucleotides, are explored in this second portion of an interview with Abzena experts.

Our top 10 videos of the year cover AI, innovation, compliance, and sustainability in biopharma.

FounderNest CEO Feliz Gonzalez breaks down where the biotech market stands today and where it’s headed in 2026

Autolomous and Trenchant’s partnership, begun early in 2025, addresses unmet CGT manufacturing needs, including slashing costs and cutting timelines.

In the first part of an extended video interview, Petra Dieterich and Jeffrey Mocny of Abzena emphasize that every part of the process of developing novel biologics is designed to bring them to humans not just quickly, but also safely.

A look at interchangeable biosimilars gaining FDA approval, the growth in global partnerships, and the rising biologics patent cliff.

Samsung Biologics’ Maryland acquisition signals a major push into US biologics manufacturing, reshaping the company’s capacity strategy and supply chain resilience.